[1] |
Duan Hongfei, Tao Yong.
Interpretation of social organization standard of Diagnosis Specification of Intraocular Tuberculosis
[J]. Chinese Journal of Antituberculosis, 2025, 47(3): 258-261.
|
[2] |
Wu Qian, Wang Wei, Zhang Yu, Chen Songhua, Chen Bin.
Construction of an evaluation indicator system for Zero Tuberculosis Community in Zhejiang Province
[J]. Chinese Journal of Antituberculosis, 2025, 47(3): 331-337.
|
[3] |
Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Inspire-CODA Research Group.
Expert consensus on the treatment of tuberculosis with contezolid
[J]. Chinese Journal of Antituberculosis, 2025, 47(2): 123-129.
|
[4] |
Zhao Yanli, Che Nanying.
Interpretation of social organization standard of Specification for Pathological Diagnosis of Tuberculosis
[J]. Chinese Journal of Antituberculosis, 2024, 46(4): 371-374.
|
[5] |
Ming Wenhua, Ma Tingting, Wang Hongtian, Wang Xueyan.
Aspirin-exacerbated respiratory diseases: pathogenesis and treatment strategies
[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1400-1405.
|
[6] |
Sha Wei.
Significance and challenges of the implementation of PAN-TB treatment strategy for tuberculosis prevention and control
[J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1188-1192.
|
[7] |
Fu Liang, Ren Tantan, Zhang Peize, Lu Shuihua.
Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update
[J]. Chinese Journal of Antituberculosis, 2023, 45(4): 336-348.
|
[8] |
Ge Qiping, Zhang Lijie, Huang Xuerui, Jiang Guanglu, Han Xiqin, Wang Jingping, Du Jian, Ma Yan, Gao Weiwei.
Effect of a new treatment regimen on patients with initially retreated drug-sensitive pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1078-1083.
|
[9] |
Gao Dan, Wang Linghua, Huang Jinpeng, Zhang Yue, Mao Xiaoxiao.
Analysis of the application effect of integrated traditional Chinese and Western medicine pulmonary rehabilitation nursing program for patients with tuberculous empyema undergoing thoracoscopic clearance
[J]. Chinese Journal of Antituberculosis, 2023, 45(10): 940-948.
|
[10] |
AN Hui-ru, WU Xue-qiong.
Interpretation of immunoadjuvant therapy in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 Edition)
[J]. Chinese Journal of Antituberculosis, 2022, 44(6): 539-543.
|
[11] |
TIAN Xiao-mei, LEI Juan, LIU Jing, LIU Guang-tian, PAN Li, LIU Tao, SHI Feng, WANG Xiao-lin.
Analysis on the effect of diagnosis and treatment management of rifampicin-resistant pulmonary tuberculosis and financing mode in Ningxia
[J]. Chinese Journal of Antituberculosis, 2021, 43(8): 772-777.
|
[12] |
LIU Zheng-wei, PENG Ying, ZHANG Ming-wu, ZHANG Yu, CHEN Song-hua, CHEN Bin, WANG Xiao-meng.
Analysis of the efficiency of tuberculosis diagnosis progress based on GeneXpert MTB/RIF application in Zhejiang Province
[J]. Chinese Journal of Antituberculosis, 2021, 43(8): 790-795.
|
[13] |
CHEN Hui, ZHANG Hui, CHENG Jun.
Interpretation of the Chinese Guidelines for Prevention and Control of Tuberculosis in Schools
[J]. Chinese Journal of Antituberculosis, 2021, 43(6): 542-545.
|
[14] |
LIU Er-yong, LI Yu-hong, ZHOU Lin, ZHAO Yan-lin.
Making panoramic plan:extra-pulmonary tuberculosis needs to be integrated into the national tuberculosis program
[J]. Chinese Journal of Antituberculosis, 2021, 43(5): 428-431.
|
[15] |
MA Yan*, GAO Wei-wei.
Pay attention to the reasonable treatment of retreatment tuberculosis:today is not what it used to be
[J]. Chinese Journal of Antituberculosis, 2021, 43(4): 313-317.
|